Antidepressant Medication Management (AMM)

CBE ID

0105

Endorsement Status

Endorsed

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

Previous Endorsement Cycle

Spring 2018

Is Under Review

Next Maintenance Cycle

Behavioral Health and Substance Use Fall 2024

1.6 Measure Description

The percentage of members 18 years of age and older who were treated antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported.

a) Effective Acute Phase Treatment. The percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).
b) Effective Continuation Phase Treatment. The percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).

Measure Specs(active tab)
Scientific Acceptability
Use & Usability
Comments

Measure Specs

General Information(active tab)
Numerator
Denominator
Exclusions
Measure Record
Point of Contact

General Information

1.7 Measure Type

Process

1.3 Electronic Clinical Quality Measure (eCQM)

1.8 Level of Analysis

Health Plan

1.20 Types of Data Sources

Claims Data

Numerator

1.14 Numerator

Adults 18 years of age and older who were newly treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment.

Denominator

1.15 Denominator

Patients 18 years of age and older with a diagnosis of major depression and were newly treated with antidepressant medication.

Exclusions

Exclude patients who use hospice services or elect to use a hospice benefit any time during the measurement year, regardless of when the services began.

Exclude patients who did not have a diagnosis of major depression in an inpatient, outpatient, ED, telehealth, intensive outpatient or partial hospitalization setting during the 121-day period from 60 days prior to the IPSD, through the IPSD and the 60 days after the IPSD.

Exclude patients who filled a prescription for an antidepressant 105 days prior to the IPSD.

Measure Record

Most Recent Endorsement Activity

Endorsed Behavioral Health and Substance Use Spring Cycle 2018

Initial Endorsement

2009-08

Last Updated

2018-10

Point of Contact

Steward Organization

National Committee for Quality Assurance

Steward POC email

measureendorsement@ncqa.org

Steward Organization Copyright

The performance measures and specifications were developed by and are owned by the National Committee for Quality Assurance (“NCQA”). The performance measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Anyone desiring to use or reproduce the materials without modification for an internal, quality improvement non-commercial purpose may do so without obtaining any approval from NCQA. All other uses, including a commercial use and/or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA.
©2018 NCQA, all rights reserved.
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.
Content reproduced with permission from HEDIS, Volume 2: Technical Specifications for Health Plans. To purchase copies of this publication, including the full measures and specifications, contact NCQA Customer Support at 888-275-7585 or visit www.ncqa.org/publications.

Importance

Equity

Feasibility

Scientific Acceptability